[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 9785 Introduced in House (IH)]

<DOC>






118th CONGRESS
  2d Session
                                H. R. 9785

   To require the Director of the Office of Management and Budget to 
 submit to Congress an annual report on biomedical research funded by 
               the United States and performed in China.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           September 24, 2024

Mr. Langworthy (for himself, Mr. Higgins of Louisiana, and Mr. Davis of 
 North Carolina) introduced the following bill; which was referred to 
the Committee on Energy and Commerce, and in addition to the Committee 
   on Agriculture, for a period to be subsequently determined by the 
  Speaker, in each case for consideration of such provisions as fall 
           within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL


 
   To require the Director of the Office of Management and Budget to 
 submit to Congress an annual report on biomedical research funded by 
               the United States and performed in China.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Chinese Laboratory Accountability 
and Watchful Spending Act of 2024'' or the ``CLAWS Act of 2024''.

SEC. 2. ANNUAL REPORT ON FEDERALLY-FUNDED BIOMEDICAL RESEARCH IN CHINA.

    (a) Definitions.--In this section:
            (1) Covered agency.--The term ``covered agency'' means--
                    (A) an Executive agency, as defined in section 105 
                of title 5, United States Code; and
                    (B) an independent regulatory agency, as defined in 
                section 3502 of title 44, United States Code.
            (2) Covered project.--The term ``covered project'' means a 
        project--
                    (A) funded by a covered agency; and
                    (B) that is awarded directly or indirectly through 
                a grant, contract, other transaction agreement, 
                subaward, cooperative agreement, or any other form of 
                assistance to an entity that--
                            (i) is located in China; or
                            (ii) performs the project in whole or in 
                        part in China.
            (3) Project.--The term ``project'' means biomedical 
        research or experimentation conducted for the identification, 
        control, treatment, and prevention of human or animal diseases, 
        including the testing of any drug, biological product, device, 
        vaccine, vaccine adjuvant, antiviral, or diagnostic test.
    (b) Requirement.--Not later than 1 year after the date of enactment 
of this Act, the Director of the Office of Management and Budget shall 
issue guidance requiring covered agencies to annually include in a 
report described in paragraph (2) of section 3516(a) of title 31, 
United States Code, or a consolidated report described in paragraph (1) 
of such section, information relating to each covered project of the 
covered agency, which shall include a detailed description of the 
covered project, including--
            (1) the purpose of the covered project;
            (2) whether the covered project involves--
                    (A) pathogens with pandemic potential;
                    (B) biological select agents and toxins;
                    (C) dual use research of concern;
                    (D) human or animal subjects; and
                    (E) classified research;
            (3) each location where the covered project is carried out 
        and, if applicable--
                    (A) whether the research location is subject to the 
                jurisdiction, direction, control, or operates on behalf 
                of the Government of the People's Republic of China; 
                and
                    (B) whether the research location engages in joint 
                research with, or is supported by, or affiliated with 
                China's military, internal security forces, or 
                intelligence agencies;
            (4) if applicable, the rationale for conducting the covered 
        project in China;
            (5) the contract or award number of the covered project;
            (6) each covered agency or subagency funding the covered 
        project;
            (7) each primary contractor, subcontractor, grant 
        recipient, and subgrant recipient of the covered project;
            (8) the start date of the covered project;
            (9) the current expected date for completion of the covered 
        project;
            (10) the cost of the covered project during the previous 
        fiscal year;
            (11) the total cost of the covered project since inception;
            (12) a description of specific steps taken to ensure 
        research security of the covered project; and
            (13) any noncompliance with respect to the covered project 
        documented by the covered agency during the reporting period.
                                 <all>